Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Catalent Announces Cell Line Sales Agreement with CEVEC

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
Deal follows study which achieved record yield for human alpha-1 antitrypsin (hAAT) molecule.

Catalent Pharma Solutions has announced that it had reached a commercial cell line sales agreement with CEVEC Pharmaceuticals for recombinant human alpha-1 antitrypsin (hAAT).

The companies have also signed a joint development and marketing agreement that combines CEVEC’s CAP® cell line, a high performance protein expression platform originally derived from primary human amniocytes and Catalent‘s GPEx® technology, a powerful gene-insertion method providing single-copy gene integration at multiple genomic locations in dividing cells.

This agreement will allow the co-promotion of the combined technologies to biotechnology companies needing cell line development and manufacturing of various proteins.

The announcements follow a successful five month study which achieved a new milestone in the field of complex protein production, having demonstrated a record yield for a non-antibody protein produced in a human expression system.

Leading global drug development and delivery solution provider Catalent, and CEVEC, the developer of a novel, market-leading human protein expression system derived from amniocytes, achieved a manufacturing yield of over 3 grams per liter for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative proprietary technologies.

The program began with the development of a GPEx based stable pool in CAP cells at Catalent, followed by initial process development at CEVEC.

“Enabling biotech companies to get clone candidates to clinic more quickly and efficiently is at the core of Catalent’s biologics business philosophy,” commented Kent Payne, Vice President and General Manager, of Catalent’s Biologics business.

Payne continued, “Having developed the hAAT molecule using our combined technologies, we have now reached a commercial agreement with CEVEC on the cell line and look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

“We are very excited to have proven the potential for generating high expressing human cell lines in a much shorter timeframe than traditional methods,” added Wolfgang Kintzel, CEO of CEVEC.

Kintzel continued, “As the yield of 3 g/L was achieved already at the stable pool stage, a further increase in productivity is expected by the ongoing generation of the clonal cell line. The high yield attained for a difficult to express and therapeutically relevant protein, such as hAAT, represents an enabling milestone for large scale manufacturing of complex proteins in human cells.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Launches FastChain Service
Company has announced the launch of its FastChain service to meet increasing need for speed & flexibility in global clinical trials.
Thursday, June 30, 2016
Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
Company provide of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services.
Friday, February 05, 2016
Catalent Announces Appointment of Sally Langa
Appointment of Ms. Langa as new Vice President of Development and Analytical Services.
Friday, January 29, 2016
Catalent to Open New Clinical Supply Facility in Japan
Construction is expected to be validated and operational in the second quarter of 2016.
Thursday, January 21, 2016
Catalent Announces Research Collaboration with Roche
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent, Roche Collaborate On SMARTag™
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Announces the Appointment of Kevin Hambly
Company appoints Mr. Hambly to the position of Vice President, Business Development and Licensing.
Tuesday, December 15, 2015
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Catalent and SELLAS Sign Exclusive Agreement
Agreement for therapeutic reprofiling of zolpidem.
Friday, December 12, 2014
Catalent and Valerion Therapeutics Collaborate
Collaboration to bring new treatments for orphan genetic disorders to market.
Thursday, December 04, 2014
Catalent Acquires Micron Technologies
Company adds global particle size technology leader to Industry’s broadest bioavailability and delivery technology offerings.
Friday, November 21, 2014
Catalent Expands Highly Potent and Cytotoxic Clinical Packaging Capabilities
Completion is expected in January 2015.
Friday, November 07, 2014
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
Link Between Canned Food, BPA Exposure Revealed
New Stanford research resolves the debate on the link between canned food and exposure to the hormone-disrupting chemical known as Bisphenol A, or BPA.
Portable Test Rapidly Detects Zika
To better diagnose and track the disease, scientists are now reporting a new $2 test that in the lab can accurately detect low levels of the virus in saliva.
Erasing Unpleasant Memories with a Genetic Switch
Researchers from KU Leuven and the Leibniz Institute for Neurobiology have managed to erase unpleasant memories in mice using a 'genetic switch'.
Unidentified Spectra Detector
New algorithm clusters over 250 million spectra for analysis, such that millions of unidentified peptide sequences can be recognised.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!